
March 11 (Reuters) - BridgeBio Pharma Inc BBIO.O:
BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9
BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026
BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO